Trial Profile
Phase 1, First-in-human, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and PK of Single and Multiple Ascending Oral Doses of XEN1101 and Preliminary Open-label Pharmacodynamic Assessment in Healthy Subjects Addendum: Phase 1, Randomised, Multi Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Relative Bioavailability and Food Effect of Single and Multiple Ascending Doses of XEN1101 and Preliminary Drug-Drug Interaction Assessment With Itraconazole
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Encukalner (Primary) ; Itraconazole
- Indications Major depressive disorder; Partial epilepsies; Tonic-clonic epilepsy
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Xenon Pharmaceuticals
- 15 May 2023 Protocol of study has been amended to increase treatment arms to 5, change trial design to non randomized, to add study parts for PK study
- 05 Jul 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified June 2018).
- 22 Feb 2021 According to a Xenon Pharmaceuticals media release, data from this trial will be presented at ASENT 2021 virtual annual meeting of the American Society for Experimental Neurotherapeutics.